PET and Cardiac Amyloidosis: Which Possible Role?

Giuseppe Vergaro, Dario Genovesi, Assuero Giorgetti, Alberto Aimo, Vincenzo Castiglione, Michele Emdin, Yu Fu Ferrari Chen, Alessandro Valleggi

Journal: PET clinics 2025;20(3):367-377

PMID: 40500100

Full Text on Elsevier Science View on PubMed

Abstract

PET has recently demonstrated promising capabilities in the diagnosis and differentiation of various forms of CA. Tracers labeled with 18F, such as 18F-flutemetamol, 18F-florbetapir, and 18F-florbetaben, are being increasingly researched due to their extended half-life, eliminating the requirement for on-site cyclotrons. Unlike bone tracers, PET amyloid-binding tracers exhibit a higher affinity for light-chain fibrils, potentially enabling accurate differentiation between various types of CA. The methodology for measuring tracer uptake in PET imaging, whether dynamic or static, facilitates the quantification of disease severity and could act as a marker for monitoring the disease, assessing treatment response.

Address: Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa 56127, Italy; Fondazione Toscana Gabriele Monasterio, Pisa 56125, Italy.; Fondazione Toscana Gabriele Monasterio, Pisa 56125, Italy.; Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa 56127, Italy.; Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa 56127, Italy; Fondazione Toscana Gabriele Monasterio, Pisa 56125, Italy. Electronic address: [email protected].

DOI: 10.1016/j.cpet.2025.04.002

Link outs

Free resources

Medical:

https://medlineplus.gov/amyloidosis.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Amyloidosis, Positron-Emission Tomography, Radiopharmaceuticals, Cardiomyopathies, Aniline Compounds, Fluorine Radioisotopes